Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam-durlobactam plus imipenem/cilastatin versus colistin plus imipenem/cilastatin for carbapenem-resistant Acinetobacter infections
2018-002526-23Phase 3Completed
- Sponsor
- Entasis Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of durlobactam and sulbactam in Acinetobacter baumannii-calcoaceticus complex infection and Bacteremia (2 arms), sponsored by Entasis Therapeutics. Primary endpoint: 28-day all-cause mortality. Started Feb 2019; status: completed.
02
Drugs
durlobactamsulbactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infectionBacteremia
Beyond the preview
Go deeper on 2018-002526-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002526-23.